Unique ID issued by UMIN | UMIN000005718 |
---|---|
Receipt number | R000006759 |
Scientific Title | Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis |
Date of disclosure of the study information | 2011/06/06 |
Last modified on | 2016/02/11 10:35:54 |
Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis
Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis
Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis
Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis
Japan |
ulcerative colitis
Gastroenterology |
Others
NO
To evaluate CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitis
Others
Clinical significance of measurement of CXCR4 expression on CD4 positive T cell as a predictive marker on the effect of leukocytapheresis
Exploratory
Pragmatic
Not applicable
CXCR4 expression on CD4 positive T cell in peripheral blood
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Device,equipment |
Patients treated with leukocytapheresis (more than once per week, total 10 sessions) therapy have a regular blood test
12 | years-old | <= |
Not applicable |
Male and Female
1) Patients with moderate, severe or intractable ulcerative colitis
2) Patients with ulcerative colitis of left side colitis or pancolitis type
3) Patients whom immunomodulator doses are not changed for two months
4) Patients that steroid doses are not increased in quantity for one week
1) Patients with proctitis
2) Patients with either white blood cell count of less than 3,000/mm3, or hemoglobin level of less than 10g/dL, or platelet count of less than 100,000/mm3
3) Patients with fulminating active ulcerative colitis (massive bleeding, perforation, toxic megacolon)
4) Patients with serious infection or cardiovascular disease or liver disease or kidney disease or respiratory disease or metabolic disease neurologic disease
5) Patients with hypotension (less than maximal blood pressure 80mmHg)
6) Patients with allergic anamnesis or experience or the fear of allergic hypersensitivity reaction
7) Patients having received inhibitor of angiotensin converting enzyme
8) Patients who are pregnant or have the possibility of pregnancy
9) Patients who are younger than 12 years old or low weight
10) Patients determined to be inappropriate for this study by the investigators
20
1st name | |
Middle name | |
Last name | Hiroshi Nakase |
Kyoto University Hospital
Division of Endoscopic Medicine
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
075-751-4319
hiropy_n@kuhp.kyoto-u.ac.jp
1st name | |
Middle name | |
Last name | Minoru Matsuura |
Kyoto University Hospital
Department of Gastroenterology and Hepatology
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
075-751-4319
minomats@kuhp.kyoto-u.ac.jp
Kyoto University Hospital
None
Self funding
NO
京都大学医学部附属病院(京都府)
2011 | Year | 06 | Month | 06 | Day |
Unpublished
Completed
2011 | Year | 05 | Month | 02 | Day |
2011 | Year | 07 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2013 | Year | 03 | Month | 31 | Day |
2011 | Year | 06 | Month | 03 | Day |
2016 | Year | 02 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006759